(Q72516382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

title

Therapeutic plasma exchange: complications and management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

author name string

M H Mokrzycki

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

A A Kaplan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

publication date

1 June 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Kidney Diseases

27 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

page(s)

817-827

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

Renal involvement in essential mixed cryoglobulinemia

27 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Controlled plasma exchange trial in acute renal failure due to multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

The complications of therapeutic plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Complications of plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Correction of hypocalcaemic symptoms during plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Dosage regimens for citrate anticoagulants.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Laboratory and clinical effects of the infusion of ACD solution during plateletpheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Calcium homeostasis during therapeutic plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasma exchange with a rotating filter

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Coagulation Abnormalities Produced by Plasma Exchange on the Cell Separator with Special Reference to Fibrinogen and Platelet Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

A comparison of centrifugal and membrane-based apheresis formats.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Intensive Plasma Exchange on the Cell Separator: Effects on Serum Immunoglobulins and Complement Components

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Effect of plasma exchange on circulating immune complexes and antibody formation in patients treated with cyclophosphamide and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Goodpasture syndrome treated with immunosuppression and plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Treatment of Goodpasture's syndrome with plasmapheresis. A case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Remission of myasthenia gravis following plasma-exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Long-term effects of repeated plasma exchange in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

The risk of transfusion-transmitted infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Transmission of retroviruses by blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Incidence and severity of anaphylactoid reactions to colloid volume substitutes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Indications of plasmapheresis and selection of different substitution solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Mortality in therapeutic haemapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

An approach to immunologic reactions associated with plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Metabolic alkalosis due to plasmapheresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Vitamin status in patients undergoing single or multiple plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Aluminium bone deposits in normal renal function patients after long-term treatment by plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Suxamethonium apnoea associated with plasmaphoresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Plasmapheresis and plasma cholinesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Anaesthesia in operations for the relief of portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Suxamethonium "extension" by tetrahydroaminacrine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Biocompatibility of different hemodialysis and plasmapheresis membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

Donor safety and plasma quality in automated plasmapheresis. Comparison of two filter materials.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980135-1

7 January 2021

10.1016/S0272-6386(12)80135-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8203364%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference